Technology
Health
Medical

Insulet

$97.18
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.66 (-0.67%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Insulet and other stocks, options, ETFs, and crypto commission-free!

About

Insulet Corporation Common Stock, also called Insulet, is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. Read More The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Employees
1,169
Headquarters
Acton, Massachusetts
Founded
2000
Market Cap
5.75B
Price-Earnings Ratio
2.02K
Dividend Yield
0.00
Average Volume
639.54K
High Today
$98.55
Low Today
$95.58
Open Price
$97.87
Volume
325.41K
52 Week High
$108.91
52 Week Low
$70.80

Collections

Technology
Health
Medical
Advertising and Marketing
Business Services
US
North America
Female CEOs

News

The Motley FoolMar 16

3 Top Healthcare Stocks to Buy in March

The healthcare market is huge. Americans alone spend more than $3 trillion each year to keep healthy. The numbers only get crazier when you include the rest of the world. A market that big is bound to create opportunities for investors. So which healthcare stocks do we have our eyes on right now? We asked a team of Motley Fool contributors to weigh in, and they called out Insulet (NASDAQ:PODD), HealthEquity (NASDAQ:HQY), and CVSHealth (NYSE:CVS). Buying this diabetes stock now could pay off Todd Campbell...

1,134
Yahoo FinanceFeb 27

Insulet (PODD) Beats Earnings and Revenue Estimates in Q4

Newmont (NEM) and Barrick's (GOLD) JV in Nevada will generate average annual pre-tax synergies worth $500 million for the first five years of the combination.

19
The Motley FoolFeb 26

Insulet Posts Positive Earnings for the Second Consecutive Quarter

Insulet (NASDAQ:PODD) reported fourth-quarter and full-year 2018 results after the market close on Monday. For the quarter, the leader in tubeless insulin pump technology delivered revenue growth of 26% year over year and earnings flipped to positive, from negative in the year-ago period. The fourth quarter marked only the second time that Insulet has posted positive quarterly earnings, with last quarter being the first. Shares edged down 1.4% in after-hours trading on Monday. We can probably attribute th...

91

Earnings

-$0.19
-$0.07
$0.04
$0.16
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 2, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.